(Q42593100)

3 November 2017

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab (English)

1 reference

3 November 2017

A M Fink

1

1 reference

3 November 2017

S Böttcher

2

1 reference

3 November 2017

M Ritgen

3

1 reference

3 November 2017

K Fischer

4

1 reference

3 November 2017

N Pflug

5

1 reference

3 November 2017

B Eichhorst

6

1 reference

3 November 2017

C-M Wendtner

7

1 reference

3 November 2017

D Winkler

8

1 reference

3 November 2017

A Bühler

9

1 reference

3 November 2017

T Zenz

10

1 reference

3 November 2017

P Staib

11

1 reference

3 November 2017

J Mayer

12

1 reference

3 November 2017

M Hensel

13

1 reference

3 November 2017

G Hopfinger

14

1 reference

3 November 2017

M Wenger

15

1 reference

3 November 2017

G Fingerle-Rowson

16

1 reference

3 November 2017

H Döhner

17

1 reference

3 November 2017

M Kneba

18

1 reference

3 November 2017

S Stilgenbauer

19

1 reference

3 November 2017

R Busch

20

1 reference

3 November 2017

M Hallek

21

1 reference

3 November 2017

21 June 2013

1 reference

3 November 2017

1 reference

3 November 2017

27

1 reference

3 November 2017

9

1 reference

3 November 2017

1949-1952

1 reference

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

3 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Risk categories and refractory CLL in the era of chemoimmunotherapy

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Understanding and managing ultra high-risk chronic lymphocytic leukemia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

TP53 mutation and survival in chronic lymphocytic leukemia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Genomic aberrations and survival in chronic lymphocytic leukemia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3768112

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23787395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23787395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.190

1 reference

Dimensions Publication ID

3 November 2017

0 references

1 reference

3 November 2017

PubMed publication ID

23787395

1 reference